Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mary-Ellen Taplin

Showing results (1-10 of 226) with videos related to

Pageof 23
Sort By:
Reviews in Urology|September 21, 2006
Biochemical (Prostate-Specific Antigen) Relapse: An Oncologist's PerspectiveMary-Ellen Taplin
Expert Review of Anticancer Therapy|September 2, 2008
Androgen receptor: role and novel therapeutic prospects in prostate cancerMary-Ellen Taplin
Reviews in Urology|September 21, 2006
Biochemical (Prostate-Specific Antigen) Relapse: An Oncologist's PerspectiveMary-Ellen Taplin
Nature Clinical Practice. Oncology|March 30, 2007
Drug insight: role of the androgen receptor in the development and progression of prostate cancerMary-Ellen Taplin
Oncology (Williston Park, N.Y.)|September 4, 2014
Secondary hormone therapy for castration-resistant prostate cancerMary-Ellen Taplin
Cancer|November 2, 2016
Prostate cancer: Developing novel approaches to castration-sensitive diseaseEdoardo Francini, Mary-Ellen Taplin
Current Opinion in Oncology|February 14, 2012
The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancerKevin D Courtney, Mary-Ellen Taplin
Clinical Genitourinary Cancer|August 6, 2011
Case report: responses to cabazitaxel in metastatic castration-resistant prostate cancer after extensive docetaxel treatmentElizabeth A Guancial, Mary-Ellen Taplin
Advances in Therapy|August 28, 2013
Abiraterone acetate: targeting persistent androgen dependence in castration-resistant prostate cancerLauren C Harshman, Mary-Ellen Taplin
Journal of Cellular Biochemistry|February 3, 2004
Androgen receptor: a key molecule in the progression of prostate cancer to hormone independenceMary-Ellen Taplin, Steven P Balk
Pageof 23

Showing results (1-10 of 226) with videos related to

Sort By:
Pageof 23
Reviews in Urology|September 21, 2006
Biochemical (Prostate-Specific Antigen) Relapse: An Oncologist's PerspectiveMary-Ellen Taplin
Expert Review of Anticancer Therapy|September 2, 2008
Androgen receptor: role and novel therapeutic prospects in prostate cancerMary-Ellen Taplin
Reviews in Urology|September 21, 2006
Biochemical (Prostate-Specific Antigen) Relapse: An Oncologist's PerspectiveMary-Ellen Taplin
Nature Clinical Practice. Oncology|March 30, 2007
Drug insight: role of the androgen receptor in the development and progression of prostate cancerMary-Ellen Taplin
Oncology (Williston Park, N.Y.)|September 4, 2014
Secondary hormone therapy for castration-resistant prostate cancerMary-Ellen Taplin
Cancer|November 2, 2016
Prostate cancer: Developing novel approaches to castration-sensitive diseaseEdoardo Francini, Mary-Ellen Taplin
Current Opinion in Oncology|February 14, 2012
The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancerKevin D Courtney, Mary-Ellen Taplin
Clinical Genitourinary Cancer|August 6, 2011
Case report: responses to cabazitaxel in metastatic castration-resistant prostate cancer after extensive docetaxel treatmentElizabeth A Guancial, Mary-Ellen Taplin
Advances in Therapy|August 28, 2013
Abiraterone acetate: targeting persistent androgen dependence in castration-resistant prostate cancerLauren C Harshman, Mary-Ellen Taplin
Journal of Cellular Biochemistry|February 3, 2004
Androgen receptor: a key molecule in the progression of prostate cancer to hormone independenceMary-Ellen Taplin, Steven P Balk
Pageof 23